We measured their systemic inflammatory markers, serum Spp1, and cytokine levels (interferon‐γ, interleukin [IL]‐1β, IL‐6, IL‐8, IL‐10, tumor necrosis factor‐α, and IL‐17A), investigated correlations between Spp1 levels and clinical features, and evaluated ALS survival rates according to Spp1 levels. This evidence concerns the gene IL17A and amyotrophic lateral sclerosis.